Home/Filings/4/0001834681-25-000005
4//SEC Filing

Pamir Ozan 4

Accession 0001834681-25-000005

CIK 0001386570other

Filed

Nov 16, 7:00 PM ET

Accepted

Nov 17, 8:23 AM ET

Size

6.7 KB

Accession

0001834681-25-000005

Insider Transaction Report

Form 4
Period: 2025-11-14
Pamir Ozan
Chief Financial Officer
Transactions
  • Purchase

    Common Stock

    2025-11-14$6.81/sh+4,464.962$30,4067,372.159 total
  • Purchase

    Common Stock

    2025-11-14$6.85/sh+2,220.443$15,2102,220.443 total(indirect: By Spouse)
Footnotes (1)
  • [F1]The weighted average purchase price for the transaction reported was $6.81, and the range of prices were between $6.7975 and $6.82, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range above will be provided.

Issuer

Niagen Bioscience, Inc.

CIK 0001386570

Entity typeother

Related Parties

1
  • filerCIK 0001834681

Filing Metadata

Form type
4
Filed
Nov 16, 7:00 PM ET
Accepted
Nov 17, 8:23 AM ET
Size
6.7 KB